Molecular and pharmacokinetic properties associated with the therapeutics of Bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin

Clinical Cancer Research

Volumn 6, Issue 7, 2000, Pages 2891-2902

  Lopes De Menezes, Daniel E ^a   Hudon, Norma ^a   McIntosh, Natashia ^a   Mayer, Lawrence D ^a,b  

^a BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DOXORUBICIN; LIPOSOME; OBLIMERSEN; PROTEIN BCL 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL DIVISION; DOXORUBICIN; DRUG CARRIERS; FEMALE; GENES, BCL-2; HUMANS; LIPOSOMES; MICE; MICE, SCID; OLIGONUCLEOTIDES, ANTISENSE; PROTO-ONCOGENE PROTEINS C-BCL-2; THIONUCLEOTIDES; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 1642618055     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Reed, J. C. Prevention of apoptosis as a mechanism of drug resistance. Hematol. Oncol. Clin. N. Am., 9: 451-473, 1995.
2. Reed, J. C. Mechanisms of apoptosis avoidance in cancer. Curr. Opin. Oncol., 11: 68-75, 1999.
3. Miyashita, T., and Reed, J. C. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood, 81: 151-157, 1993.
4. Zamzami, N., Brenner, C., Marzo, I., Susin, S. A., and Kroemer, G. Subcellular and submitochondrial mode of action of Bcl-2-like proteins. Oncogene, 16: 2265-2282, 1998.
5. Reed, J. C., Miyashita, T., Takayama, S., Wang, H. G., and Sato, T. Bcl-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J. Cell. Biochem., 60: 23-32, 1996.
6. Reed, J. C. Bcl-2: prevention of apoptosis as a mechanism of drug resistance. Hematol. Oncol. Clin. N. America., 9: 451-473, 1995.
7. Berardo, M. D., Elledge, R. M., Moor, C., Clark, G. M., Osborne, C. K., and Allred, D. C. Bcl-2 and apoptosis in lymph node positive breast carcinoma. Cancer (Phila.), 82: 1296-1302, 1998.
8. Webb, A., Cunningham, D., Cotter, F., Clarke, P. A., di Stefano, F., Ross, P., Corbo, M., and Dziewanowska, Z. Bcl-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet, 349: 1137-1141, 1997.
9. Zamecnik, P. C., and Stephenson, M. L. Inhibition of Rous sarcoma virus replication and cell transformation by a oligodeoxynucleotide. Proc. Natl. Acad. Sci. USA., 75: 280-284, 1978.
10. Wintersberger, U. Ribonucleases H of retroviral and cellular origin. Pharmacol. Ther., 48: 259-280, 1990.
11. Miyashita, T., and Reed, J. C. bcl-2 gene transfer increases relative resistance of S49.1 and WEH17.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res., 52: 5407-5411, 1992.
12. Kamesaki, S., Kamesaki, H., Jorgensen, T. J., Tanizawa, A., Pommier, Y., and Cossman, J. bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair. Cancer Res., 53: 4251-4256, 1993.
13. Walton, M. I., Whysong, D., O'Connor, P. M., Hockenbery, D., Korsmeyer, S. J., and Kohn, K. W. Constitutive expression of human Bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis. Cancer Res., 53: 1853-1861, 1993.
14. Dean, N. M., and Griffey, R. H. Identification and characterization of second-generation antisense oligonucleotides. Antisense Nucleic Acid Drug Dev., 7: 229-233, 1997.
15. Agrawal, S., Temsamani, J., and Tang, J. Y. Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc. Natl. Acad. Sci. USA, 88: 7595-7599, 1991.
16. Raynaud, F. I., Orr, R. M., Goddard, P. M., Lacey, H. A., Lancashire, H., Judson, I. R., Beck, T., Bryan, B., and Cotter, F. Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice. J. Pharmacol. Exp. Ther., 281: 420-427, 1997.
17. Webb, S. J., Harrison, D. J., and Wylie, A. H. Apoptosis: an overview of the process and its relevance in disease. In: S. Kaufmann (ed.), Apoptosis, Pharmacological Implications and Therapeutic Opportunities, pp. 1-34. London: Academic Press, 1997.
18. Zangemeister-Witte, U., Schenker, T., Luedke, G. H., and Stahel, R. A. Synergistic cytotoxicity of Bcl-2 antisense oligodeoxynucleotide and etoposide, doxorubicin and cisplatin in small-cell lung cancer cell lines. Br. J. Cancer., 78: 1035-1042, 1998.
19. Jansen, B., Schlagbauer-Wadl, H., Brown, B. D., Bryan, R. N., van Elsas, A., Muller, M., Wolff, K., Eichler, H., and Pehamberger, H. Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat. Med., 4: 232-234, 1998.
20. Cotter, F. E., Johnson, P., Hall, P., Pocock, C., Al Mahdi, N., Cowell, J. K., and Morgan, G. Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. Oncogene, 9: 3049-3055, 1994.
21. Allen, T. M., Hansen, C., Martin, F., Redemann, C., and Yau-Young, A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim. Biophys. Acta, 1066: 29-36, 1991.
22. Papahadjopoulos, D., Allen, T. M., Gabizon, A., Mayhew, E., Mattahay, K., Huang, S. K., Lee, K-D., Woodle, M. C., Lasic, D. D., Redemann, C., and Martin, F. J. Sterically stabilized liposomes: improvements in phamacokinetics and antitumor therapeutic efficacy. Proc. Natl. Acad. Sci. USA, 88: 11460-11464, 1991.
23. Martin, F. Clinical pharmacology and antitumor efficacy of DOXIL (pegylated liposomal doxorubicin). In: D. D. Lasic and D. Papahadjopoulos (eds.), Medical Applications of Liposomes, pp. 635-688. New York: Elsevier, 1998.
24. Yuan, F., Leunig, M., Huang, S. K., Berk, D. A., Papahadjopoulos, D., and Jain, R. K. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res., 54: 3352-3356, 1994.
25. Leonessa, F., Green, D., Licht, T., Wright, A., Wingate-Legette, K., Lippman, J., Gottesman, M. M., and Clarke, R. MDA435/LCC6 and MDA435/LCC6MDR1: ascites models of human breast cancer. Br. J. Cancer, 73: 154-161, 1996.
26. Derksen, J. T. P., Morselt, H. W. M., and Scherphof, G. L. Processing of different liposome markers after in vitro uptake of immunoglobulin-coated liposomes by rat liver macrophages. Biochim. Biophys. Acta, 931: 33-40, 1987.
27. Mayer, L. D., Hope, M. J., and Cullis, P. R. Vesicles of variable sizes produced by a rapid extrusion procedure. Biochim. Biophys. Acta, 858: 161-168, 1986.
28. Mayer, L. D., Bally, M. B., and Cullis, P. R. Uptake of Adriamycin into large unilamellar vesicles in response to a pH gradient. Biochim. Biophys. Acta, 857: 123-126, 1986.
29. Mayer, L. D., Tai, L. C. L., Ko, D. S. C., Masin, D., Ginsberg, R. S., Cullis, P. R., and Bally, M. B. Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. Cancer Res., 49: 5922-5930, 1989.
30. Krishna, R., and Mayer, L. D. Liposomal doxorubicin circumvents PSC833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors. Cancer Res., 57: 5246-5253, 1997.
31. Yang, D., Ling, Y., Almazan, M., Guo, R., Murray, A., Brown, B., and Lippman, M. E. Tumor regression of human breast carcinomas by combination therapy of anti-Bcl-2 antisense oligonucleotide and chemotherapeutic drugs. Proc. Am. Assoc. Cancer Res., 40: 729, 1999.
32. L protein in primary breast cancer is associated with high tumor grade and nodal metastases. Cancer J. Sci. Am., 3: 230-237, 1997.
33. Tu, Y., Renner, S., Xu, F., Fleishman, A., Taylor, J., Weisz, J., Vescio, R., Rettig, M., Berenson, J., Krajewski, S., Reed, J. C., and Lichtenstein, A. Bcl-X expression in multiple myeloma: possible indicator of chemoresistance. Cancer Res., 58: 256-262, 1998.
34. Haq, R., and Zanke, R. Inhibition of apoptotic signaling pathways in cancer cells as a mechanism of chemotherapy resistance. Cancer Metastasis Rev., 17: 233-239, 1998.
35. Miyake, H., Tolcher, A., and Gleave, M. Antisense Bcl-2 oligonucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model. Cancer Res., 59: 4030-4034, 1999.
36. Taxeira, C., Reed, J. C., and Pratt, M. A. C. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells, Cancer Res. 55: 3902-3907, 1995.
37. Tolcher, A., Miyake, H., and Gleave, M. E. Down-regulation of Bcl-2 expression by antisense oligonucleotide (AS-ODN) treatment enhances mitoxantrone cytotoxicity in the androgen-dependent Shionogi tumor model. Proc. Am. Assoc. Cancer Res., 40: 3198, 1999.
38. Weiner, G. J., Liu, H. M., Wooldridge, J. E., Dahle, C. E., and Krieg, A. M. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc. Natl. Acad. Sci. USA, 94: 10833-10837, 1997.
39. Ballas, Z. K., Rasmussen, W. L., and Krieg, A. M. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA, J. Immunol., 157: 1840-1845, 1996.
40. Klasa, R. J., Bally, M. B., Ng, R., Goldie, J. H., Gascoyne, R., and Wong, F. M. P. Eradication of human non-Hodgkin's lymphoma in SCID mice by Bcl-2 antisense oligonucleotides combined with low-dose cyclophosphamide, Clin. Cancer Res., in press, 2000.